

KOVO+ HOLDINGS INC.

NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING

(the “Notice of Meeting”)

Notice is hereby given that the annual general and special meeting (the “**Meeting**”) of the shareholders (the “**Shareholders**”) of Kovo+ Holdings Inc. (formerly Kovo HealthTech Corporation) (the “**Corporation**”) will be held at the offices of Dentons Canada LLP, 850 2nd St SW, 15th Floor, Calgary, Alberta T2P 0R8, on Monday, December 16, 2024 at 10:00 a.m. (MST) for the following purposes:

1. to receive and consider the financial statements of the Corporation for the year ended December 31, 2023, and the auditors’ reports thereon;
2. to fix the number of directors to be elected at the Meeting at four (4) members;
3. to elect four (4) directors of the Corporation for the ensuing year;
4. to reappoint the auditors of the Corporation for the ensuing year and to authorize the directors to fix their remuneration;
5. to consider and, if deemed advisable, pass, with or without variation, a special resolution to approve the continuance of the Corporation out of the jurisdiction of British Columbia under the *Business Corporations Act* (British Columbia) and into the jurisdiction of Alberta under the *Business Corporations Act* (Alberta), as described in the accompanying management information circular (the “**Information Circular**”); and
6. to transact such further and other business as may properly come before the Meeting or any adjournment or adjournments thereof.

The specific details of the matters proposed to be put before the Meeting are set forth in the Information Circular, which accompanies and forms part of this Notice of Meeting.

A Shareholder may attend the Meeting in person or may be represented at the Meeting by a proxyholder. Shareholders who are unable to attend the Meeting are requested to date and sign the enclosed instrument of proxy (the “**Instrument of Proxy**”) and mail or deposit it with Computershare Trust Company of Canada (“**Computershare**”), our transfer agent. To be valid, the Instrument of Proxy must be dated, completed, signed and deposited with Computershare by: (i) mail to 8th Floor, 100 University Avenue, Toronto, Ontario, M5J 2Y1 Attention: Proxy Department; (ii) phone at 1-866-732-8683 (Toll-Free Canada & U.S.) or 1-312-588-4290 (Toll-Free International), entering the 15-digit control number found on your Instrument of Proxy; or (iii) online at www.investorvote.com, entering the 15-digit control number found on your Instrument of Proxy, or as otherwise indicated in the instructions contained in the Instrument of Proxy. In order to be valid and acted upon at the Meeting, Instruments of Proxy must be received not less than 48 hours (excluding Saturdays, Sundays and holidays) before the time set for the holding of the Meeting or any adjournment thereof. Shareholders are cautioned that using mail to transmit proxies is at each Shareholder’s risk.

The board of directors of the Corporation (the “**Board**”) has fixed the record date for the Meeting at the close of business on November 8, 2024 (the “**Record Date**”). Shareholders of record as at the Record Date are entitled to receive notice of the Meeting and to vote those Common Shares included in the list of shareholders entitled to vote at the Meeting prepared as at the Record Date, unless any such Shareholder transfers Common Shares after the Record Date and the transferee of those Common Shares, having produced properly endorsed certificates evidencing such Common Shares or having otherwise established that he or she owns such Common Shares, demands, not later than 10 days before the Meeting, that the transferee’s name be included in the list of Shareholders entitled to vote at the Meeting, in which case such transferee shall be entitled to vote such Common Shares at the Meeting.

Shareholders have the right to dissent with respect to the continuance of the Corporation (the “**Dissent Rights**”) pursuant to the *Business Corporations Act* (British Columbia) (the “**BCBCA**”). In order to validly exercise the Dissent Rights, Shareholders must strictly comply with the dissent procedures enumerated in Sections 237 to 247 of the BCBCA, as further described in the accompanying Information Circular.

DATED this 15th day of November, 2024.

BY ORDER OF THE BOARD OF DIRECTORS

(signed) “*Peter Bak*”

Peter Bak

Board Chair